Wall Street brokerages expect REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) to announce $26.00 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for REGENXBIO’s earnings, with estimates ranging from $22.04 million to $28.47 million. REGENXBIO posted sales of $22.04 million in the same quarter last year, which suggests a positive year-over-year growth rate of 18%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that REGENXBIO will report full-year sales of $152.31 million for the current financial year, with estimates ranging from $105.80 million to $217.10 million. For the next year, analysts expect that the company will report sales of $233.49 million, with estimates ranging from $105.80 million to $403.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for REGENXBIO.
REGENXBIO (NASDAQ:RGNX – Get Rating) last released its earnings results on Tuesday, March 1st. The biotechnology company reported $6.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.28 by $2.39. REGENXBIO had a net margin of 21.38% and a return on equity of 17.92%. The company had revenue of $398.66 million for the quarter, compared to analyst estimates of $255.76 million. During the same period in the prior year, the firm earned ($1.24) EPS. The firm’s quarterly revenue was up 1759.0% on a year-over-year basis.
RGNX has been the subject of several research analyst reports. Morgan Stanley reduced their target price on REGENXBIO from $51.00 to $47.00 and set an “overweight” rating for the company in a research note on Tuesday. Chardan Capital restated a “buy” rating on shares of REGENXBIO in a research note on Monday, April 11th. StockNews.com assumed coverage on REGENXBIO in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research lowered REGENXBIO from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, TheStreet lowered REGENXBIO from a “c” rating to a “d+” rating in a research report on Monday, May 16th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, REGENXBIO presently has an average rating of “Hold” and an average target price of $45.38.
RGNX opened at $20.18 on Friday. The firm has a 50 day moving average price of $27.49 and a 200 day moving average price of $28.83. The company has a market cap of $870.44 million, a PE ratio of 9.39 and a beta of 1.12. REGENXBIO has a 1 year low of $18.69 and a 1 year high of $46.46.
A number of hedge funds have recently made changes to their positions in RGNX. New York State Teachers Retirement System boosted its stake in REGENXBIO by 0.9% in the fourth quarter. New York State Teachers Retirement System now owns 45,631 shares of the biotechnology company’s stock worth $1,492,000 after purchasing an additional 400 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in REGENXBIO by 101.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 277,700 shares of the biotechnology company’s stock worth $9,081,000 after purchasing an additional 139,947 shares in the last quarter. Comerica Bank boosted its stake in REGENXBIO by 3.4% in the third quarter. Comerica Bank now owns 32,298 shares of the biotechnology company’s stock worth $1,167,000 after purchasing an additional 1,072 shares in the last quarter. Geode Capital Management LLC raised its position in shares of REGENXBIO by 0.4% during the third quarter. Geode Capital Management LLC now owns 665,419 shares of the biotechnology company’s stock worth $27,894,000 after acquiring an additional 2,711 shares during the last quarter. Finally, Voloridge Investment Management LLC bought a new stake in shares of REGENXBIO during the third quarter worth $3,706,000. 87.57% of the stock is currently owned by institutional investors and hedge funds.
About REGENXBIO (Get Rating)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REGENXBIO Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for REGENXBIO and related companies with MarketBeat.com’s FREE daily email newsletter.